Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Acquisitions & Divestments: 2016-2023

Historic Change in Acquisitions & Divestments for Cartesian Therapeutics (RNAC) over the last 4 years, with Mar 2023 value amounting to $28.3 million.

  • Cartesian Therapeutics' Change in Acquisitions & Divestments rose 182.54% to $28.3 million in Q1 2023 from the same period last year, while for Mar 2023 it was $48.0 million, marking a year-over-year increase of 26.53%. This contributed to the annual value of $28.3 million for FY2023, which is 43.42% up from last year.
  • As of Q1 2023, Cartesian Therapeutics' Change in Acquisitions & Divestments stood at $28.3 million, which was up 395.68% from $5.7 million recorded in Q4 2022.
  • Cartesian Therapeutics' Change in Acquisitions & Divestments' 5-year high stood at $28.3 million during Q1 2023, with a 5-year trough of $2.0 million in Q1 2019.
  • In the last 3 years, Cartesian Therapeutics' Change in Acquisitions & Divestments had a median value of $8.2 million in 2021 and averaged $10.7 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first slumped by 86.76% in 2019, then spiked by 182.54% in 2023.
  • Over the past 4 years, Cartesian Therapeutics' Change in Acquisitions & Divestments (Quarterly) stood at $11.5 million in 2019, then reached $10.0 million in 2021, then plummeted by 43.00% to $5.7 million in 2022, then surged by 182.54% to $28.3 million in 2023.
  • Its last three reported values are $28.3 million in Q1 2023, $5.7 million for Q4 2022, and $4.0 million during Q3 2022.